Therapies for Psoriasis: Clinical and Economic Comparisons

J Drugs Dermatol. 2020;19(11):1101-1108. doi:10.36849/JDD.2020.5510

Albert Marchetti MD, Tina Bhutani MD, Benjamin Lockshin MD, Daniel M. Siegel MD, Frederick Behringer MD

Clinical and economic comparisons of therapies for plaque psoriasis are regularly updated following each new development in the field. Among study comparators, the 308nm excimer laser is safe and delivers incremental clinical benefits with the potential for significant cost savings.

Efficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis

J Drugs Dermatol. 2020;19(9):874-880. doi:10.36849/JDD.2020.5020

Leon H. Kircik MD, Todd E. Schlesinger MD FAAD, Emil Tanghetti MD

In the treatment of moderate plaque psoriasis, Cal/BD foam plus apremilast provided more benefits than with apremilast alone. These improvements appeared to be lost when Cal/BD foam was withdrawn but recovered when Cal/BD foam was reinitiated.

Increased Trend of Cosmetic Procedures in Patients With Psoriasis Who Attain 75% or Greater Improvement

J Drugs Dermatol. 2020;19(8): doi:10.36849/JDD.2020.5104R1

Michelle E. Walters MD, Delphine J. Lee MD PhD, Paul S. Yamauchi MD PhD

The relationship between the clearance of psoriasis and improved quality of life together with an increased uptake of cosmetic procedures has not been reported to date. A survey was conducted to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance.

Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis

J Drugs Dermatol. 2020;19(8):741-746. doi:10.36849/JDD.2020.5116

Phoebe Rich MD, Orin Goldblum MD, Damon Disch PhD, Chen-Yen Lin PhDb, Joseph F. Merola MD, Boni Elewski MD

Presence of nail psoriasis in patients with plaque psoriasis may be an indicator of greater disease severity. Previously, patients with nail psoriasis have had delayed skin clearance after treatment compared to patients without nail psoriasis. This post-hoc analysis evaluated the efficacy of ixekizumab in clearance of plaque psoriasis in patients with and without nail psoriasis.

The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)

J Drugs Dermatol. 2020;19(8): doi:10.36849/JDD.2020.5337

M. Alan Menter MD, Nehal N. Mehta MD MSCE FAHA, Mark G. Lebwohl MD, Alice B. Gottlieb MD PhD, Alan M. Mendelsohn MD, Stephen J. Rozzo PhD, Craig Leonardi MD

Metabolic syndrome (MetS) is the most prevalent comorbidity in psoriasis and increases the risk of cardiovascular disease, diabetes, and mortality. Assessment of impacts of biologic therapies on cardiometabolic risk factors are relatively limited. This study evaluated the effect of tildrakizumab on cardiometabolic risk factors in patients with moderate to severe plaque psoriasis and stratified by MetS status.

The New Psoriasis Paradigm: Striving for Complete Clearance

J Drugs Dermatol. 2020;19(6): doi:10.36849/JDD.2020.4975

Leon H. Kircik MD

Newer biologics have introduced the possibility of higher and more complete clearance rates than previously possible. For many patients, PASI 90 and PASI 100 responses are realistic. Furthermore, higher levels of clearance, particularly total clearance, is associated with marked improvements in quality of life. Little data is available on the clinical benefits of higher clearance levels and how this might relate to improvements in other comorbidities. Is it time for dermatologists to strive for total clearance for our patients?

Evaluation of Patient-Reported Outcomes with Etanercept in Moderate to Severe Plaque Psoriasis Patients After Therapy With Apremilast

J Drugs Dermatol. 2020;19(4): doi:10.36849/JDD.2020.4910

Jerry Bagel, Bradley S. Stolshek, Yue Yang,b Gregory Kricorian, and Leon Kircik

Should patient-reported improvements in psoriasis and satisfaction with psoriasis treatment be considered along with traditional clinical measures when assessing patients?

Recapture Rate of Brodalumab in Patients With a Lapse in Treatment

J Drugs Dermatol. 2020;19(4): doi:10.36849/JDD.2020.5026

Mark Lebwohl MD, Jennifer Cather MD, April Armstrong MD MPH, Abby Van Voorhees MD, Abby Jacobson PA-C

This review discusses the efficacy and safety of brodalumab and other biologic therapies in patients with psoriasis who stop and restart treatment. These clinically relevant and important findings can help inform real-world treatment decisions.

Efficacy and Safety of Systemic Treatments for Skin and Joint Manifestations in Patients With Psoriasis

J Drugs Dermatol. 2020;19(3): doi:10.36849/JDD.2020.4690

William Abramovits MD, Joel Schlessinger MD

This narrative review discusses the efficacy and safety of systemic treatments for skin and joint manifestations in patients with psoriasis to provide dermatologists and rheumatologists with an updated summary of the benefits and risks of currently available treatments on several disease domains.

Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials

J Drugs Dermatol. 2019;18(8):804-813.

Andrew F. Alexis MD MPH, Marta Rendon MD, Jonathan I. Silverberg MD, David M. Pariser MD, et al.

Dupilumab, a monoclonal antibody that blocks the shared receptor subunit for interleukin (IL)-4 and IL-13, is currently approved for the treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis (AD).

Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis

J Drugs Dermatol. 2019;18(8):790-796.

Neal Bhatia MD,a Linda Stein Gold MD,b Leon H. Kircik MD,c Rhonda Schreiber MSd

A novel foam formulation of halobetasol propionate, 0.05% (HBP-Foam) has been developed to treat plaque psoriasis in patients who prefer a thermostable topical foam with low application shear that allows for easier coverage over large and/or hirsute areas than existing formulations.

Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis

J Drugs Dermatol. 2019;18(8):776-788.

Lawrence J. Green MD,ª Paul S. Yamauchi MD PhD,b Leon H. Kircik MDc

Psoriasis (PsO) is a common, systemic, chronic inflammatory disease characterized by key clinical symptoms, including itching, pain, and scaling, and is associated with substantial physical, psychosocial, and economic health burdens. Currently, there is no cure for PsO; however, the introduction of biologic therapies has revolutionized the clinical management of patients with PsO by expanding treatment options to include multiple therapies with different mechanisms of action targeting cytokines, including tumor necrosis factor inhibitors (TNFis), interleukin (IL)-17A inhibitors, an IL-12/23 inhibitor, and IL-23 inhibitors.

Combination Use of Systemic Therapies in Psoriasis: Baseline Characteristics from the Corrona Psoriasis Registry

J Drugs Dermatol. 2019;18(8):731-740.

Lauren Bonomo MD,a Brian J. Abittan MD,a Peter W. Hashim MD,a Chitra Karki MPH,c Marc Mason MS,c Mark Lebwohl MDa

Importance: There are increasing options for systemic combination therapy for psoriasis but a lack of literature around the characteristics of patients who are started on these regimens.

Onset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis

J Drugs Dermatol. 2018;17(3):247-250.

Kim A. Papp MD PhDa and Mark G. Lebwohl MDb

The advent of biologics has improved patient outcomes in the treatment of moderate-to-severe psoriasis. The time it takes for patients to see clinically meaningful improvement is an important aspect of disease management.